Advertisement

Renal Mass Biopsy is Associated with Reduction in Surgery for Early-Stage Kidney Cancer

Published:September 16, 2019DOI:https://doi.org/10.1016/j.urology.2019.08.043

      ABSTRACT

      Objective

      To determine whether use of renal mass biopsy may be associated with a reduction in surgery for patients with small, localized renal cell carcinoma (cT1aN0M0), especially among older patients and patients with greater comorbidity burden.

      Methods

      A total of 106,258 patients with cT1aN0M0 renal cell carcinoma from 2004 to 2015 were analyzed in the National Cancer Data Base. Multivariable logistic regression identified independent associations with nonsurgical management, receipt of biopsy, and pathologic upstaging. Marginal effects were derived by age and comorbidity. A sensitivity analysis was conducted in years identifying patients undergoing active surveillance (2010-2015).

      Results

      There was increased use of biopsy (8.0%-15.3%) and nonsurgical management (11.7%-15.6%) over time. Biopsy was significantly associated with use of nonsurgical management (OR 4.80 [95%CI 4.58-5.02], P <.001) as well as active surveillance (OR 1.87 [1.69-2.07], P <.001) in the sensitivity analysis. Individual predicted probability of undergoing nonsurgical management ranged from 3% to 92% (median 31.4% with use of biopsy) and increased with age and comorbidity. Pathologic tumor upstaging (≥pT3a) occurred more frequently for patients receiving biopsy compared to no biopsy (5.8% vs 3.3%, P <.001). After adjustment, biopsy remained a statistically significant predictor of upstaging (OR 1.31 [95%CI 1.24-1.38], P <.001).

      Conclusion

      Overall, biopsy demonstrated a strong, independent association with reduced use of surgery for cT1aN0M0 kidney cancer, especially with increasing age and comorbidity. The potential association of renal mass biopsy with upstaging warrants caution, but it is uncertain whether it impacts prognosis relative to true perinephric fat invasion.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ferlay J
        • Ervik M
        • Lam F
        • et al.
        Global Cancer Observatory: Cancer Today.
        International Agency for Research on Cancer, Lyon, France2018 (Available from:) (accessed [01 January 2019])
        • Chow WH
        • Devesa SS
        • Warren JL
        • Fraumeni Jr., JF
        Rising incidence of renal cell cancer in the United States.
        JAMA. 1999; 281: 1628-1631
        • Patel HD
        • Gupta M
        • Joice GA
        • et al.
        Clinical stage migration and survival for renal cell carcinoma in the United States.
        Eur Urol Oncol. 2019; 2: 343-348
        • Pierorazio PM
        • Patel HD
        • Johnson MH
        • et al.
        Distinguishing malignant and benign renal masses with composite models and nomograms: A systematic review and meta-analysis of clinically localized renal masses suspicious for malignancy.
        Cancer. 2016; 122: 3267-3276
        • Patel HD
        • Johnson MH
        • Pierorazio PM
        • et al.
        Diagnostic accuracy and risks of biopsy in the diagnosis of a renal mass suspicious for localized renal cell carcinoma: systematic review of the literature.
        J Urol. 2016; 195: 1340-1347
        • Maturen KE
        • Nghiem HV
        • Caoili EM
        • et al.
        Renal mass core biopsy: accuracy and impact on clinical management.
        AJR Am J Roentgenol. 2007; 188: 563-570
        • Patel HD
        • Pierorazio PM
        Kidney cancer: undertreatment of small renal masses by overuse of biopsy.
        Nat Rev Urol. 2016; 13: 701-703
        • Bilimoria KY
        • Stewart AK
        • Winchester DP
        • Ko CY
        The National Cancer Data Base: a powerful initiative to improve cancer care in the United States.
        Ann Surg Oncol. 2008; 15: 683-690
        • Patel HD
        • Riffon MF
        • Joice GA
        • et al.
        A prospective, comparative study of quality of life among patients with small renal masses choosing active surveillance and primary intervention.
        J Urol. 2016; 196: 1356-1362
        • Halverson SJ
        • Kunju LP
        • Bhalla R
        • et al.
        Accuracy of determining small renal mass management with risk stratified biopsies: confirmation by final pathology.
        J Urol. 2013; 189: 441-446
        • Alam R
        • Patel HD
        • Osumah T
        • et al.
        Comparative effectiveness of management options for patients with small renal masses: a prospective cohort study.
        BJU Int. 2019; 123: 42-50
        • Pandharipande PV
        • Gervais DA
        • Hartman RI
        • et al.
        Renal mass biopsy to guide treatment decisions for small incidental renal tumors: a cost-effectiveness analysis.
        Radiology. 2010; 256: 836-846
        • Campbell S
        • Uzzo RG
        • Allaf ME
        • et al.
        Renal mass and localized renal cancer: AUA guideline.
        J Urol. 2017; 198: 520-529
        • Ljungberg B
        • Albiges L
        • Abu-Ghanem Y
        • et al.
        European Association of Urology Guidelines on renal cell carcinoma: the 2019 update.
        Eur Urol. 2019; 75: 799-810
        • Patel HD
        • Semerjian A
        • Gupta M
        • et al.
        Surgical removal of renal tumors with low metastatic potential based on clinical radiographic size: a systematic review of the literature.
        Urol Oncol. 2019; (Epub ahead of print)https://doi.org/10.1016/j.urolonc.2019.05.013
        • Srivastava A
        • Patel HD
        • Joice GA
        • et al.
        Incidence of T3a up-staging and survival after partial nephrectomy: size-stratified rates and implications for prognosis.
        Urol Oncol. 2018; 36: 12.e7-12.e13
        • Andersen MF
        • Norus TP
        Tumor seeding with renal cell carcinoma after renal biopsy.
        Urol Case Rep. 2016; 9: 43-44
        • Laird A
        • Couper CH
        • Glancy S
        • et al.
        Renal cell carcinoma needle biopsy: sowing the seed for later complications?.
        BMJ Case Rep. 2014; 2014 (bcr2014203691)
        • Richard PO
        • Lavallée LT
        • Pouliot F
        • et al.
        Is routine renal tumor biopsy associated with lower rates of benign histology following nephrectomy for small renal masses?.
        J Urol. 2018; 200: 731-736
        • Gorin MA
        • Rowe SP
        • Baras AS
        • et al.
        Prospective evaluation of (99m)Tc-sestamibi SPECT/CT for the diagnosis of renal oncocytomas and hybrid oncocytic/chromophobe tumors.
        Eur Urol. 2016; 69: 413-416
        • Campbell SP
        • Tzortzakakis A
        • Javadi MS
        • et al.
        99mTc-sestamibi SPECT/CT for the characterization of renal masses: a pictorial guide.
        Br J Radiol. 2018 Apr; 9120170526